Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma, a specialty biopharmaceutical company, has terminated the licensing agreement signed in 2007 with SpeBio, a joint venture with SpePharm.
Subscribe to our email newsletter
The exclusive license in EU countries other than France covered the distribution of Loramyc, a muco-adhesive buccal tablet for treating in oropharyngeal candidiasis, a type of infected mucositis, in immunodepressed patients.
BioAlliance Pharma has also initiated legal proceedings in Paris against SpeBio for violation of the latter’s contractual obligations and in order to obtain appropriate compensation for losses suffered as a result of delays in commercialization and sale of Loramyc.
BioAlliance Pharma is confident in ensuring the continued Europe-wide commercialization of Loramyc directly in selected countries and through specialist oncology partners in other countries.
Dominique Costantini, president and CEO of BioAlliance, said: “Loramyc has been a clear success in France during its first year on sale and we believe in the product’s potential in markets throughout Europe.”